SLC5A2 and type 2 diabetes mellitus: From a retrospective cohort of 122,458 people with type 2 diabetes, established CVD and heart failure in the US, combination therapy reduced the composite of all-cause mortality, myocardial infarction and non-fatal stroke by 67% within one year compared with propensity score matched subjects treated with SGLT-2 inhibitors alone [32].